FDA grants expanded indication for Deep TMS for treatment of depression in older adults

Key Takeaways:

• Deep TMS has received expanded indication for the treatment of major depressive disorder in patients aged 22 to 86 years.
• The device is the first form of TMS indicated for patients aged older than 68 years.

The FDA has granted an expanded indication for BrainsWay’s Deep Transcranial Magnetic Stimulation system for depression treatment in patients aged 22 to 86 years, according to a company press release.

Deep TMS is the first and only TMS device indicated for the treatment of major depressive disorder in patients aged older than 68 years.

“As life expectancies rise, BrainsWay’s FDA label expansion for Deep TMS to treat depression up to age 86 brings hope, enhancing the quality of life for patients living longer as well as their families and caregivers,” Colleen A. Hanlon, PhD, vice president of medical affairs at BrainsWay, told Healio.